Unknown

Dataset Information

0

Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.


ABSTRACT: Tumor neovascularization is targeted by inhibition of vascular endothelial growth factor (VEGF) or the receptor to prevent tumor growth, but drug resistance to angiogenesis inhibition limits clinical efficacy. Inhibition of the phosphoinositide 3 kinase pathway intermediate, mammalian target of rapamycin (mTOR), also inhibits tumor growth and may prevent escape from VEGF receptor inhibitors. mTOR is assembled into two separate multi-molecular complexes, mTORC1 and mTORC2. The direct effect of mTORC2 inhibition on the endothelium and tumor angiogenesis is poorly defined. We used pharmacological inhibitors and RNA interference to determine the function of mTORC2 versus Akt1 and mTORC1 in human endothelial cells (EC). Angiogenic sprouting, EC migration, cytoskeleton re-organization, and signaling events regulating matrix adhesion were studied. Sustained inactivation of mTORC1 activity up-regulated mTORC2-dependent Akt1 activation. In turn, ECs exposed to mTORC1-inhibition were resistant to apoptosis and hyper-responsive to renal cell carcinoma (RCC)-stimulated angiogenesis after relief of the inhibition. Conversely, mTORC1/2 dual inhibition or selective mTORC2 inactivation inhibited angiogenesis in response to RCC cells and VEGF. mTORC2-inactivation decreased EC migration more than Akt1- or mTORC1-inactivation. Mechanistically, mTORC2 inactivation robustly suppressed VEGF-stimulated EC actin polymerization, and inhibited focal adhesion formation and activation of focal adhesion kinase, independent of Akt1. Endothelial mTORC2 regulates angiogenesis, in part by regulation of EC focal adhesion kinase activity, matrix adhesion, and cytoskeletal remodeling, independent of Akt/mTORC1.

SUBMITTER: Farhan MA 

PROVIDER: S-EPMC4546419 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.

Farhan Maikel A MA   Carmine-Simmen Katia K   Lewis John D JD   Moore Ronald B RB   Murray Allan G AG  

PloS one 20150821 8


Tumor neovascularization is targeted by inhibition of vascular endothelial growth factor (VEGF) or the receptor to prevent tumor growth, but drug resistance to angiogenesis inhibition limits clinical efficacy. Inhibition of the phosphoinositide 3 kinase pathway intermediate, mammalian target of rapamycin (mTOR), also inhibits tumor growth and may prevent escape from VEGF receptor inhibitors. mTOR is assembled into two separate multi-molecular complexes, mTORC1 and mTORC2. The direct effect of mT  ...[more]

Similar Datasets

| S-EPMC9068620 | biostudies-literature
| S-EPMC5620061 | biostudies-literature
| S-EPMC7299339 | biostudies-literature
| S-EPMC5898915 | biostudies-literature
| S-EPMC6381131 | biostudies-literature
| S-EPMC6770602 | biostudies-literature
| S-EPMC5669570 | biostudies-literature
| S-EPMC7543065 | biostudies-literature
| S-EPMC5934775 | biostudies-literature
| S-EPMC2884035 | biostudies-literature